Claims
- 1. A method for identifying an agonist or antagonist of an SP9155 receptor, comprising:
(a) contacting the SP9155 receptor or a functional fragment thereof, in the presence of a known amount of labeled SP9155 receptor ligand, with a sample to be tested for the presence of said agonist or antagonist; and (b) measuring the amount of the ligand specifically bound to the receptor; whereby the sample is identified as containing an antagonist or an agonist by measuring substantially reduced binding of the labeled ligand to the receptor, compared to what would be measured in the absence of the sample.
- 2. The method of claim 1 wherein the labeled ligand is a carboxy-terminally amidated polypeptide comprising an amino acid sequence selected from SEQ ID NOs: 4-11 and 13-18.
- 3. The method of claim 1 wherein the receptor comprises the amino acid sequence of SEQ ID NO: 2 or of SEQ ID NO: 20.
- 4. The method of claim 1 in which the source of the receptor comprises a membrane isolated from a mammalian cell comprising said receptor.
- 5. A method for identifying an agonist or antagonist of an SP9155 receptor comprising:
(a) contacting a cell expressing the SP9155 receptor or a functional fragment thereof, in the presence of a known amount of SP9155 receptor ligand, with a sample to be tested for the presence of said agonist or antagonist; and (b) measuring calcium mobilization by the cell; whereby the sample is identified as containing an antagonist by measuring substantially reduced calcium mobilization compared to what would be measured in the absence of the sample and whereby the sample is identified as containing an agonist by measuring substantially increased calcium mobilization compared to what would be measured in the absence of the sample.
- 6. The method of claim 5 wherein the ligand is a carboxy-terminally amidated polypeptide comprising an amino acid sequence selected from SEQ ID NOs: 4-11 and 13-18.
- 7. The method of claim 5 wherein the receptor comprises the amino acid sequence of SEQ ID NO: 2 or of SEQ ID NO: 20.
- 8. The method of claim 5 wherein the calcium mobilization is measured by contacting the calcium with a calcium indicator and then measuring fluorescence of said indicator.
- 9. The method of claim 8 wherein the calcium indicator is 1-[2-Amino-5-(2,7-dichloro-6-hydroxy-3-oxy-9-xanthenyl)phenoxy]-2-(2′-amino-5′- methylphenoxy)ethane-N,N,N′,N′-tetraacetic acid, pentaacetoxymethyl ester.
- 10. A method for making a polypeptide comprising culturing a host cell comprising a recombinant vector which vector comprises a nucleic acid encoding an antigenic polypeptide comprising 7 or more contiguous amino acids from SEQ ID NO: 4 or from SEQ ID NO: 13 under conditions in which the nucleic acid is expressed.
- 11. The method of claim 10 in which the polypeptide is isolated from the culture.
- 12. A method for forming a complex between an antigenic peptide comprising 7 or more contiguous residues of an amino acid sequence selected from SEQ ID NOs: 4 and 13 and an antibody molecule which specifically binds said peptide comprising contacting said peptide with said antibody molecule.
- 13. A method for treating or preventing a medical condition in a subject mediated by the SP9155 receptor comprising administering, to the subject, a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof which specifically binds to a polypeptide comprising 7 or more contiguous amino acids from SEQ ID NO: 4 or from SEQ ID NO: 13 and a pharmaceutically acceptable carrier.
- 14. The method of claim 13 wherein the medical condition is selected from pain and obesity.
- 15. An isolated antigenic polypeptide comprising 7 or more contiguous residues of an amino acid sequence selected from SEQ ID NOs: 4 and 13.
- 16. An isolated polypeptide comprising an amino acid sequence selected from SEQ ID NOs: 4-11 and 13-18
- 17. An isolated antigenic polypeptide of claim 15 which is carboxy-terminally amidated.
- 18. An antibody or functional fragment thereof which specifically binds to a polypeptide of claim 15.
- 19. An isolated nucleic acid which encodes a polypeptide of claim 15.
- 20. A nucleic acid of claim 19 which encodes a polypeptide comprising an amino acid sequence selected from SEQ ID NOs: 4-11 and 13-18.
- 21. A nucleic acid of claim 20 which comprises a nucleotide sequence selected from SEQ ID NOs: 3 and 12.
- 22. A recombinant vector comprising the nucleic acid of claim 19.
- 23. A host cell comprising the vector of claim 22.
- 24. A pharmaceutical composition comprising the polypeptide of claim 15 and a pharmaceutically acceptable carrier.
- 25. A pharmaceutical composition comprising the antibody molecule of claim 18 and a pharmaceutically acceptable carrier.
Parent Case Info
[0001] This Application claims the benefit of U.S. Provisional Patent Application No. 60/372,640, filed Apr. 12, 2002, now pending, which is herein incorporated by reference in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60372640 |
Apr 2002 |
US |